Literature DB >> 6988070

Fusidic acid: new opportunities with an old antibiotic.

J D Anderson.   

Abstract

The extensive foreign experience with fusidic acid prior to its belated introduction to Canada is reviewed. Fusidic acid is a steroid antibiotic with minimal toxic and hormonal effects that is mainly excreted through the liver. It has a predominantly bactericidal action and does not shown cross-resistance with other antibiotics. Since organisms resistant to this drug form easily in vitro when exposed to low concentrations, complementary treatment with another antibiotic may be required in some clinical situations. Although fusidic acid is active in vitro against a number of organisms, to date it has mainly been used to treat serious infections due to Staphylococcus aureus. The agent appears to be particularly valuable in the treatment of bone and joint infections and in pediatric practice. Fusidic acid will soon be available in Canada for both oral and intravenous administration. Attainable antibiotic levels in many tissues and body fluids greatly exceed the minimum inhibitory concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988070      PMCID: PMC1801889     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  34 in total

1.  Purpura after warfarin.

Authors:  J R Moore
Journal:  Lancet       Date:  1967-09-02       Impact factor: 79.321

2.  Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis.

Authors:  G L Wright; J Harper
Journal:  Lancet       Date:  1970-01-03       Impact factor: 79.321

3.  Further experience in the management of chronic osteomyelitis.

Authors:  D E Rowling
Journal:  J Bone Joint Surg Br       Date:  1970-05

4.  On the mode of action of fusidic acid.

Authors:  C L Harvey; S G Knight; C J Sih
Journal:  Biochemistry       Date:  1966-10       Impact factor: 3.162

5.  Estimation of sodium fusidate levels in human serum, aqueous humour, and vitreous body.

Authors:  J Williamson; F Russell; W M Doig; R W Paterson
Journal:  Br J Ophthalmol       Date:  1970-02       Impact factor: 4.638

6.  Intraocular penetration of the antibiotic fucidin.

Authors:  A J Chadwick; B Jackson
Journal:  Br J Ophthalmol       Date:  1969-01       Impact factor: 4.638

7.  [Acute puerperal mastitis treated with Fucidin].

Authors:  O Lauen
Journal:  Tidsskr Nor Laegeforen       Date:  1969-06-01

8.  Combined treatment with antibacterial chemotherapeutical agents in staphylococcal infections.

Authors:  K Jensen; H C Lassen
Journal:  Q J Med       Date:  1969-01

9.  Fucidin, pro-staphlin, and penicillin concentration in burn crusts.

Authors:  B Sorensen; P Sejrsen; M Thomsen
Journal:  Acta Chir Scand       Date:  1966-06

10.  Naturally-occurring fusidic acid resistance in staphylococci and its linkage to other resistances.

Authors:  R J Evans; P M Waterworth
Journal:  J Clin Pathol       Date:  1966-11       Impact factor: 3.411

View more
  9 in total

1.  Compulsory reporting changing MDs' role in sexual-abuse cases.

Authors:  C Johnston
Journal:  CMAJ       Date:  1991-05-01       Impact factor: 8.262

2.  Analgesics and chronic pain: "if all you have is a hammer, every disease is a nail".

Authors:  B Goldman
Journal:  CMAJ       Date:  1991-06-15       Impact factor: 8.262

3.  Gastric myiasis. Role of the lesser housefly.

Authors:  J M Blondeau; D J Haldane; U Murray; K P Buchholz
Journal:  Can Fam Physician       Date:  1993-03       Impact factor: 3.275

4.  Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus.

Authors:  Ronald N Jones; Mariana Castanheira; Paul R Rhomberg; Leah N Woosley; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2010-01-06       Impact factor: 5.948

5.  In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Pharmacokinetics of intravenous fusidic acid in patients with cholestasis.

Authors:  J D Peter; F Jehl; T Pottecher; J P Dupeyron; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.

Authors:  David J Farrell; Rodrigo E Mendes; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  The Prevalence and Determinants of Fusidic Acid Resistance Among Methicillin-Resistant Staphylococcus aureus Clinical Isolates in China.

Authors:  Huilin Zhao; Xinyi Wang; Bingjie Wang; Yanlei Xu; Lulin Rao; Baoshan Wan; Yinjuan Guo; Xiaocui Wu; Jingyi Yu; Liang Chen; Meilan Li; Fangyou Yu
Journal:  Front Med (Lausanne)       Date:  2021-11-30

9.  Comparison of Disk Diffusion and Etest Methods to Determine the Susceptibility of Staphylococcus aureus Circulating in Riyadh, Saudi Arabia to Fusidic Acid.

Authors:  Ali M Somily; David R Peaper; Elijah Paintsil; Thomas S Murray
Journal:  Int J Microbiol       Date:  2012-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.